respiratory syncytial virus (RSV)

View All

beyfortus-for-respiratory-syncytial-virus-treatment
Beyfortus: A New Respiratory Syncytial Virus (RSV) Drug for Toddlers

Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...

Find More

gsk-respiratory-syncytial-virus-vaccine
GSK Is All Set To Launch Respiratory Syncytial Virus Vaccine… Now Who’s Next?

Infections due to respiratory syncytial virus (RSV) have seriously troubled drug makers for decades and the need for a vaccine was on since the 1960s. According to the assessment done by DelveInsight on the latest published “Respiratory Syncytial Virus Epidemiology Report,” it is estimated to affect approximately 5...

Find More

emerging-vaccines-for-respiratory-syncytial-virus-treatment
Respiratory Syncytial Virus Treatment Market: A Complex Space Worth Billions!

Respiratory syncytial virus is estimated to affect approximately 5 million cases this year in the United States and 2.5 million RSV cases in the EU4 countries and the United Kingdom. As per Delveinsight analysis on the latest published “Respiratory Syncytial Virus Epidemiology Report,” the US comprised ~70%, ~27%, ...

Find More

Pharma News and Updates BioXcel, Eton, Gilead, Pfizer, Alembic, Telix
BioXcel’s Agitation Drug Igalmi; FDA Approves Cysteine Hydrochloride Injection; Gilead’s Trodelvy; Alembic Pharma’s Topical Anesthetic Cream; Pfizer Acquires ReViral; Telix Buys Lilly’s Failed Cancer Drug Lartruvo

FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Disorder. Igalmi (dexmedetomidine) is the first drug approved for this application that comes in the form of a tablet that...

Find More

Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug

Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...

Find More